![Daniel Karp](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Daniel Karp
Directeur/Membre du Conseil chez
CARTESIAN GROWTH CORPORATION II
Fortune : 942 375 $ au 31/07/2026
Profil
Daniel Karp is currently an Independent Director at Cartesian Growth Corp.
II since 2022 and Executive Vice President-Corporate Development at Organon & Co. Former positions include Independent Director at Cartesian Growth Corp., Vice President-Worldwide Business Development at Pfizer Inc. from 2016 to 2018, and Executive Vice President-Corporate Development at Biogen, Inc. from 2018 to 2020.
Education includes an undergraduate degree from Duke University and an MBA from The Wharton School of the University of Pennsylvania.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ORGANON & CO. 0,03 % | 15/06/2026 | 69 548 ( 0,03 % ) | 942 375 $ | 31/07/2026 |
Postes actifs de Daniel Karp
| Sociétés | Poste | Début |
|---|---|---|
| CARTESIAN GROWTH CORPORATION II | Directeur/Membre du Conseil | 01/05/2022 |
| ORGANON & CO. | Corporate Officer/Principal | - |
Anciens postes connus de Daniel Karp
| Sociétés | Poste | Fin |
|---|---|---|
| BIOGEN INC. | Corporate Officer/Principal | 01/05/2020 |
| PFIZER INC. | Corporate Officer/Principal | 01/06/2018 |
| ALVARIUM TIEDEMANN A | Directeur/Membre du Conseil | - |
Formation de Daniel Karp
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
99
Relations au 1er degré
7
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Pfizer Inc.
 Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Duke University
 Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Wharton School of the University of Pennsylvania
 The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cartesian Growth Corp.
 Cartesian Growth Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
Organon & Co.
 Organon & Co. Pharmaceuticals: MajorHealth Technology Develops and delivers women health, trusted legacy brands and therapeutics | Health Technology |
Cartesian Growth Corp. II
 Cartesian Growth Corp. II Financial ConglomeratesFinance Operates as a blank check company | Finance |
